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Abstract
The presence of more than one non-severe pathogenic mutation in the same mitochondrial
DNA (mtDNA) molecule is very rare. Moreover, it is unclear whether their co-occurrence
results in an additive impact on mitochondrial function relative to single mutation
effects. Here we describe the first example of a mtDNA molecule harboring three Leber's
hereditary optic neuropathy (LHON)-associated mutations (m.11778G>A, m.14484T>C,
m.11253T>C) and the analysis of its genetic, biochemical and molecular characterization in
transmitochondrial cells (cybrids). Extensive characterization of cybrid cell lines harboring
either the 3 mutations or the single classic m.11778G>A and m.14484T>Cmutations
revealed no differences in mitochondrial function, demonstrating the absence of a synergis-
tic effect in this model system. These molecular results are in agreement with the ophthal-
mological characteristics found in the triple mutant patient, which were similar to those
carrying single mtDNA LHONmutations.
Introduction
Mitochondrial complex I is the largest and least understood component of the oxidative phosphor-
ylation (OXPHOS) system. It is the entry point for electrons into the respiratory chain and couples
the transfer of electrons from NADH+H+ to CoQ with proton pumping across the mitochondrial
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intermembrane space. Complex I produces approximately 40% of the proton-motive force and is
considered the major mitochondrial source of reactive oxygen species (ROS) [1].
Considerable progress has been made in recent years towards understanding the structure
and function of complex I. Complex I has a characteristic L-shape structure with a hydropho-
bic arm embedded in the mitochondrial inner membrane and a peripheral hydrophilic arm
that protrudes into the mitochondrial matrix. It can be organized in four modules according to
their function: the NADH-oxidation and the quinone-reduction modules localized in the
peripheral arm, and two proton-pumping modules forming the membrane arm, which are des-
ignated as proximal and distal according to the distance to the peripheral arm. The energy nec-
essary for proton pumping is generated by the redox reactions occurring in the modules of the
peripheral arm, where the flavin mononucleotide (FMN) cofactor accepts electrons from
NADH+H+ and passes them to the CoQ reduction site, in a flow whereby electrons lose part of
their energy that is used by the proton-pumping modules [2–5].
Human complex I consists of 45 subunits, of which 7 are encoded in the mitochondrial
DNA (mtDNA) and the remaining 38 are encoded by the nuclear genome and later imported
into mitochondria. All complex I mtDNA-encoded proteins are highly hydrophobic and are
members of the proton pumping modules [6]. Mutations in any of the 45 subunits, or in the
factors that assemble them, are candidates for complex I deficiencies (phenotype MIM
#252010), the most common group of OXPHOS disorders in humans [7]. Mutations in
mtDNA produce a remarkable spectrum of associated phenotypes, from weak single disease to
devastating syndromes, due to the intrinsic nature of mitochondrial genetics and the specific
energy requirements of the different cell types affected [8]. The most common mtDNA-associ-
ated complex I disease is Leber´s hereditary optic neuropathy (LHON; MIM #535000).
LHON is a maternally-inherited form of retinal ganglion cell degeneration that leads to
optic atrophy and loss of central vision. LHON was the first human pathology to be associated
with a mtDNA point mutation [9]. Currently, three mtDNA point mutations, the so-called
three primary or common LHONmutations, affecting subunits of complex I, are described to
be responsible for 95% of LHON cases: m.3460G>A, m.11778G>A and m.14484T>C [10].
Although literature on complex I deficiency and mitochondrial dysfunction induced by these
primary mutations is extensive, the data is also somewhat contentious, particularly regarding
the severity of such alterations. This could be in part due to the comparison of different param-
eters (such as mitochondrial ATP synthesis or oxygen consumption), biological sources (such
as muscle biopsies, lymphoblasts, fibroblasts or hybrids, among others), and techniques utilized
(such as spectrophotometry for in vitro respiratory chain complex activity and in vivo respira-
tion, or phosphorus magnetic resonance spectroscopy (31P-MRS)) [11].
In addition to the three primary mutations, approximately 30 different point mutations
have been associated with LHON and are classified into two groups; the “top-14”, which
include the three primary mutations, and a group of single family or singleton cases, such as
the m.11253T>C mutation described in this study.
LHON has an incomplete penetrance and commonly presents a delayed onset, which
implies that the phenotypic expression may involve other factors in addition to the known
mutations, such as the nuclear and mitochondrial genetic background, environmental and age-
related factors [12–14].
The presence of three concomitant pathogenic mutations in a single mtDNA molecule has
not been described in the literature, and therefore comparisons with similar situations are chal-
lenging. However, the presence of two non-severe mtDNA mutations in the same molecule,
although also very rare, has been described in a few LHON cases. Accordingly, the co-occur-
rence of two of the three primary LHONmutations has been detected in five families (Table 1,
row A) [15–18]. Furthermore, four studies have described the concomitant presence of one of
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the three common LHONmutations together with one of the remaining “top-14” LHON
mutations (Table 1, row B) [19–22]. Finally, there are several cases of LHON patients (exam-
ples are shown in Table 1 row C) simultaneously harboring one of the three primary LHON
mutations and a non-LHON related mtDNAmutation, including m.1555A>G, associated
with aminoglycoside-induced non-syndromic hearing loss [23, 24], a common deletion related
to progressive external ophthalmoplegia (PEO) and Kearns–Sayre syndrome (KSS) [25], or
m.12192G>A, associated with cardiomyopathy [26].
As shown in Table 1, 7 out of 9 of these studies suggest a possible synergistic effect of the
mutations strictly based on the clinical penetrance and a possible involvement of the nuclear
background. The two remaining studies suggest that there are no synergistic effects between
LHONmutations, based only on clinical observations. None of the studies carried out a com-
plete biochemical analysis and only one [15] performed biochemical assays to measure com-
plex I-linked respiration and in vitro activity. Nevertheless, this limited analysis was sufficient
to indicate a synergistic effect between m.11778G>A and m.14484T>C mutations.
Table 1. Synergistic effect of concomitant mtDNAmutations with at least one LHON-associated mutation. All mutations and their classifications are
described in MITOMAP [10].
Mutationsa Heteroplasmy (%) Synergy Evidence Functional studies Reference
A
m.11778G>A m.3460G>A - 100 / 10 Suggested clinical No [17]
m.11778G>A m.14484T>C - (23–77)b/ 100 No clinical No [16]
m.11778G>A m.14484T>C - (94/31)c/ 100 Yes biochemical Yesd [15]
m.11778G>A m.14484T>C - 100/ (70/30)c NDe ND No [12]
B
m.11778G>A m.14502T>C - ND Suggested clinical No [22]
m.11778G>A m.14502T>C - 100 / 100 Suggested ND No [21]
m.11778G>A m.14502T>C - 100 / 100 Suggested clinical No [19]
m.11778G>A m.14484T>C - (100 / 100) Suggested clinical No [20]
C
m.11778G>A m.1555A>G - 100 / 100 Suggestedf clinical No [24]
m.14484T>C m.1555A>G - 100 / 100 Suggestedf clinical No [23]
m.11778G>A common deletion - 100 / (0–62)g NO clinical No [25]
m.11778G>A m.12192G>A - 100 / 100 Suggestedf clinical No [26]
D
m.11778G>A m.14484T>C m.11253T>C 100/100/100 NO biochemical Yes This work
a) In all rows, the ﬁrst mutation belongs to the three primary LHON mutations (>95% of LHON cases). Row A, the second mutation also belongs to the
three primary LHON mutations. Row B, the second mutation belongs to the remaining “top-14” primary LHON mutations. Row C, some of the cases in
which the second mtDNA mutation is not described to be associated with LHON but instead to other mitochondrial diseases, such as aminoglycoside-
induced non-syndromic hearing loss (m.1555A>G), progressive external ophthalmoplegia (PEO) and Kearns–Sayre syndrome (KSS) ( 5kb common
deletion) and cardiomyopathy (m.12192G>A). Row D, the triple LHON mutation described in this study; two mutations belong to the three primary LHON
mutations and the third is associated with LHON in a single family (see text).
b) Range in two families analyzed.
c) Proband/asymptomatic mother of the proband
d) Complex I dependent respiration and complex I in vitro activity
e) ND: no data or authors do not comment.
f) Affecting only LHON, not hearing loss, phenotype. Proband did not present hearing loss symptoms
g) Common deletion is absent in mtDNA from blood, 58% in orbicularis oculi muscle and 62% in quadriceps femoris muscle
doi:10.1371/journal.pone.0146816.t001
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Although a recent extensive analysis of pathogenic LHONmutations [27] did not strictly
describe LHON cases based on double mutations, the authors established a putative relation-
ship between LHONmutations belonging to the “top-14”group (excluding the three common
mutations), a series of presumed polymorphic variants and haplogroups of the mtDNA mole-
cules. Indeed, the authors discussed a potential synergistic role of some polymorphisms on pri-
mary mutations based on their conservation patterns. However, no functional analyses were
carried out to establish this.
Here we report a comprehensive molecular characterization of a homoplasmic triple LHON
mutation in comparison with single primary mutations and haplogroup-specific controls in a
nucleus and environment independent manner. We generated mutant transmitochondrial
cybrid cell lines harboring the m.11778G>A (ND4, J1c haplogroup) and m.14484T>C (ND6,
Uk1) single mutations and the concomitant m.11778G>A / m.14484T>C / m.11253T>C tri-
ple mutation (ND4, ND6, ND4; TRIPLE, H). All cybrid cells were made by fusing platelets
from donors with the immortalized 143B cell line depleted of mtDNA (143B ρ0) [28].
Our results show a robust defect in mitochondrial function for all the cybrids carrying
LHONmutations, but no synergistic effect of the triple LHON case compared with cybrids
harboring only one primary mutation. This is consistent with the ophthalmological character-
istics found in the triple LHON patient, which are no more severe than the phenotype found in
LHON families harboring a single mtDNA mutation.
Materials and Methods
Probands
The triple LHON proband was a 27-year-old woman who experienced slight bilateral vision
loss at age 9, with papillary pallor and central scotomas in both eyes. At 22 years of age, optical
coherence tomography (OCT) showed a severe loss of thickness of the papillary retinal nerve
fiber layer (RNFL). In the last few years, clinical parameters (visual acuity, scotomas, RNFL,
papillary pallor, refraction) stabilized, with no additional ophthalmological characteristics of
classical LHON symptoms or associated neurological alterations such as headache, eye pain,
weakness, or other relevant health disorders.
The patients harboring m.11778G>A and m.14484T>Cmutations showed classical LHON
symptoms, such as bilateral visual dysfunction, vascular tortuosity of the central retinal vessels,
scotomas, and no pain on eye movement. No other relevant symptoms were found.
The work described here was carried out in accordance with the Declaration of Helsinki for
experiments involving human samples http://www.wma.net/en/30publications/10policies/b3/
index.html. The only human samples used in this work were blood samples for platelet purifi-
cation and fusion as described. The ethics committees of the Hospital 12 de Octubre and Uni-
versidad Autónoma de Madrid approved the study. Written informed consent for research
purposes was obtained from all patients.
Cell lines and growth conditions
To perform a precise analysis of the functional effect of mtDNA mutations, we minimized the
influence of the nuclear background by isolating and confirming the absence of mtDNA and
mitochondrial function in single expanded osteosarcoma 143B ρ0 cell, which was used as a pro-
genitor for all transmitochondrial fusions. Cybrids were generated by fusion with platelets as
described elsewhere [28, 29]. Briefly, platelets were centrifugated (15°C, 1,500 x g for 15 min)
from plasma and 106 ρ0 cells in 2 ml of complete media were carefully added to the platelet pel-
let followed by centrifugation at 180 x g for 10 min. The resulting pellet was resuspended in
100 μL of 42% polyethylene glycol, incubated for 1 min, and cultured in 10 ml of complete
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Dulbeco´s modified Eagle´s medium (DMEM, Life Technologies) as described below. After
fusion for 12 hours, cells were grown in selective medium without uridine. Individual clones
were isolated by limiting dilution and mtDNA was analyzed by RFLP mapping and
sequencing.
Seven different cell lines were constructed in total; three from donors harboring the
individual mutations m.11778G>A (ND4, J1c), m.14484T>C (ND6, Uk1) and the triple
m.11778G>A / m.14484T>C / m.11253T>C (TRIPLE, H) mutation, and four cell lines from
healthy donors with the corresponding haplogroups, K (J1c), K (Uk1), and two for K (H) from
different pedigrees. All experiments were performed with two independent clones of each line
at least in triplicate, therefore avoiding as much as possible a putative clonal effect [29, 30]. To
exclude differences due to mtDNA levels after fusion, all cell lines were evaluated for mtDNA
copy number several times during experiments. No significant differences were detected after
stabilization (data not shown) and all experiments were performed with the cell lines at a simi-
lar passage number.
Cells were maintained in complete DMEM supplemented with 4.5 g/l glucose, 10% FBS,
50 μg/mL uridine and antibiotics. Prior to experiments, cells were cultured for 24 h in DMEM
containing 2 g/L glucose and 2.5 g/L galactose (Glu/Gal medium). Cell lines were checked rou-
tinely for mycoplasma contamination.
Genetic analysis
Patient DNA was extracted from blood using the DNeasy Blood and Tissue Kit (Qiagen).
mtDNA was amplified from total DNA in 24 overlapping PCR fragments of approximately
800 bp in length, and both strands were sequenced. mtDNA sequence analysis was carried out
using the revised Cambridge Reference Sequence (rCRS) of human mitochondrial DNA (Gen-
Bank number NC_012920) as a reference. mtDNA samples were classified into mtDNA hap-
logroups according to their sequence [31]. No LHON-associated mutations other than those
described [10] were found in the mtDNA samples.
Primary LHONmutations were analyzed by RFLP in all cybrid lines from patients and
healthy donors. PCR conditions were: 30 cycles of 55°C for annealing and 15 sec of polymeriza-
tion. For m.11778G>A, the forward primer (5´-TTCACCGGCGCAGTCATTCTCATAA-3´)
and the reverse primer (5´-TGTTGTGGTAAATATGTAGAG-3´) generate a 317 bp product
containing an internal LweI recognition site in wild-type molecules, whose digestion generates
fragments of 223 bp and 94 bp. For m.14484T>C, the forward primer (5´-ATAGCCATCGCT
GTAGTATATCCAAAGACAACGA-3´) and the reverse primer (5´-CCGTGCGAGAATAAT
GATGTATGC-3´) generate a 236 bp product including a MboI restriction site in wild-type
molecules, which generates fragments of 202 bp and 34 bp. All RFLP assays were carried out
with positive and negative controls. Diagnostic restriction endonuclease digestions were
resolved by 2% or 3% agarose gel electrophoresis for the m.11778G>A and the m.14484T>C,
respectively. The m.11253T>Cmutation was analyzed by sequencing the 271 bp mtDNA
fragment obtained by PCR using as forward primer 5´-CCACACTTATCCCCACCTTG-3´
and 5´-AAGTGGAGTCCGTAAAGAGGTATC-3´ as a reverse primer with the same PCR
conditions as above, but with an annealing temperature of 60°C.
Growth curves
Cell growth was measured in cells seeded in 6-well plates at an initial density of 25,000 cells/
well. Growth was monitored over 4 days in DMEM containing either 4.5 g/L glucose or 0.9 g/L
galactose as a carbon source. Cells were harvested and counted every 24 hours.
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Oxygen consumption
The basal respiration of intact cells was measured at 37°C in Glu/Gal DMEM using a Clark-
type oxygen electrode (Hansatech Instruments) as described [32]. At least three independent
recordings were obtained to generate a mean.
Lactate production
Lactate was measured in cell culture medium following a 48-h culture period as previously
described [33]. Briefly, 1x105 cells were plated per well in a 6-well plate in Glu/Gal DMEM.
After 48 h, 50 μL of the medium was removed, deproteinized and frozen until measurement.
Lactate was determined with a lactate dehydrogenase-based activity assay (Roche), which
results in the production of NADH and an increase in absorbance at 340 nm that is propor-
tional to the lactate present in the samples. The concentration of lactate calculated with a stan-
dard curve was normalized to the total amount of protein in the culture dishes measured with
the Micro BCA Protein Assay Kit (Thermo Scientific). Assays were performed in triplicate in
three independent experiments.
ATP steady-state measurement
Mitochondrial steady-state ATP levels were measured in cells previously incubated with 5 mM
2-deoxy-D-glucose/1 mM pyruvate using the luminometric luciferin-luciferase-based method
(CLS II, Roche Applied Science) as described elsewhere [34]. Experiments were performed in
duplicate on at least three independent days.
Measurement of ROS and MIMP
Mitochondrial superoxide production was measured using MitoSOXTM Red (Invitrogen). The
mitochondrial inner membrane potential (MIMP) was evaluated as the ratio of tetramethyl
rhodamine ester (TMRE, Invitrogen) and MitoTracker Green (MTG, Invitrogen). To perform
these assays, 0.75x105 cells were grown in Glu/Gal DMEM. After addition of the fluorophores
(5 μMMitoSOXTM Red or 100 nM TMRE and 100 nMMTG) and incubation at 37°C for 30
min in the dark, the cells were collected in Glu/Gal DMEM and analyzed immediately with a
Cytomic FC500 MPL flow cytometer (Beckman Coulter). Forward and side scatter were used
to gate the viable population of cells and the mean fluorescence intensity was determined with
MXP software (Beckman Coulter). Experiments were performed in duplicate on at least three
independent passages.
Enzymatic activity of OXPHOS complexes assays
The activity of the OXPHOS complexes and the enzyme citrate synthase was determined as
previously described [35] using a Beckman Coulter DU 800 spectrophotometer.
Complex I assembly
Blue native-polyacrylamide gel electrophoresis (BN-PAGE) and two-dimensional
BN-SDS-PAGE analysis of OXPHOS complexes was performed as previously described [36].
For two-dimensional BN-SDS-PAGE experiments, cells were grown with 10 μg/ml chloram-
phenicol (Sigma) for 2 days to deplete respiratory chain complexes. Cells were then collected
48 h after chloramphenicol removal. The detection of fully-assembled complexes was carried
out by western blotting after BN-PAGE using anti-NDUFA9 and anti-CII 70 kDa antibodies
(Invitrogen, Mitosciences).
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[Ca2+]M measurements
The Ca2+-sensitive photoprotein aequorin was used to measure mitochondrial [Ca2+]
([Ca2+]M). Cells were plated in 13-mm round coverslips and transfected for expression of mito-
chondrially-targeted low-Ca2+-affinity aequorin (see [37] for more details). Twenty-four-hours
later, cells were incubated in standard medium (145 mMNaCl, 5 mM KCl, 1 mMMgCl2,
1 mM CaCl2, 10 mM glucose and 10 mMHEPES, pH 7.4) for 1–2 h with 1 μM coelenterazine
for aequorin reconstitution. Cells were then placed in the perfusion chamber of a purpose-built
luminometer. For stimulation of intact cells, cells were perfused with standard medium con-
taining an agonist (100 μM histamine). For experiments with permeabilized cells, standard
medium containing 0.5 mM EGTA instead of Ca2+ was perfused for 1 min, followed by 1 min
perfusion with intracellular medium (130 mM KCl, 10 mM NaCl, 1 mMMgCl2, 1 mM potas-
sium phosphate, 0.5 mM EGTA, 5 mM L-malate, 5 mM glutamate, 20 mMHepes pH 7) con-
taining 100 μM digitonin. Then, intracellular medium without digitonin was perfused for
5 min, followed by perfusion with a 4.5 μM [Ca2+] buffer obtained using an EDTA/Ca2+/Mg2+
mixture. The temperature was set to 37°C. Calibration of the luminescence data into [Ca2+]
was made using an algorithm adjusted to the calibration of the aequorin form used, as
described [37]. Assays were performed in duplicate with at least three independent
experiments.
Statistics
The results were presented as the mean ± SD. Statistical analysis was performed using one-way
ANOVA and Tukey’s multiple comparison test. A p-value<0.05 was considered as significant.
Results
Comparison of mtDNAmolecules
Although literature on LHONmutations is extensive, it is somewhat confusing and on occa-
sion controversial with regards to molecular and clinical consequences. Thus, complex I defi-
ciency varies from 0% to 80% depending on the technical approach used (enzyme activity,
ATP synthesis, oxygen consumption, growth on galactose, among others), the system studied
(lymphoblasts, platelets, leukocytes, transmitochondrial cybrids), the genetic background
(nuclear and mitochondrial) and other factors, including environmental factors [11].
To eliminate as much as possible the involvement of modifying factors, we generated trans-
mitochondrial cybrids harboring different mtDNA mutations and haplogroup-specific con-
trols. This, we believe, permits the most accurate comparison among mtDNAmolecules.
Similarly, culturing these cells under controlled conditions removes possible environmental
factors. In addition, since cybridizations were performed using a common progenitor clone of
143B-ρ0, a cell line previously isolated and genetically and functionally confirmed, all cybrids
in this study contain an identical nuclear background. To overcome the potential clonal vari-
ability during cybridization [29, 30], we analyzed at least two different clones for each cell line.
Thus, the functional behaviour of all cybrid cell lines used (Table 2) is the result of different
mtDNA molecules against the same nuclear background and under identical experimental
conditions.
Mitochondrial function
Diseases caused by mtDNA mutations present a complex and broad range of clinical and bio-
chemical phenotypes. We therefore analyzed different features of the bioenergetic status of
cybrid cell lines. Results from the mutant cell lines were compared with those obtained from
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their corresponding controls to assess the effect of the mutation without any modifying ele-
ments, including haplogroups.
As a first approach, we compared their ability to grow using glucose or galactose as a carbon
source. All cybrid cell lines showed comparable growth rates after 4 days in high glucose
medium (Fig 1A); however, when cells were switched to galactose medium, forcing a depen-
dence on mitochondrial function [38], the cybrid lines with LHONmutations showed a clear
growth defect compared with control cells. No significant differences were found between the
triple LHON cybrids and single mutants (Fig 1A).
Glycolysis and oxidative metabolism are highly regulated in the vast majority of cells. A
decrease in oxidative metabolism capacity, such as that resulting from mtDNAmutation,
reduces pyruvate flux into mitochondria, forcing its transformation to lactate [39]. Because lac-
tate is balanced inside and outside of the cell by monocarboxylate transporters [40], the oxida-
tive metabolism state can be assessed by measuring lactate levels in culture medium. Culture
medium from mutant cell lines contained significantly more lactate (approximately 40%) as
compared with their corresponding controls. Moreover, this increase was comparable in all
mutant cybrid lines independent of the mutation (Fig 1B).
The electrical potential or charge density of the mitochondrial inner membrane is a good
indicator of the correct function of the electron transport chain (ETC). To measure this, we
used flow cytometry to calculate the TMRE/MTG ratio in cells. TMRE is an inner membrane
potential-dependent fluorescent dye that is readily sequestered by active mitochondria. Since
the signal emitted by TMRE is dependent on mitochondrial mass, MTG (a membrane poten-
tial-insensitive mitochondrial mass dye) is loaded in the same experiment to measure the
charge/ mitochondrial mass relationship. A significant decrease in the TMRE/MTG ratio
(approximately 40%) was detected in all mutant lines as compared with their corresponding
controls. Again, no differences were detected between the mutations (Fig 1C).
To further investigate the mitochondrial molecular defects associated with LHONmuta-
tions, we next analyzed the respiratory chain capacity by measuring oxygen consumption in
intact cells. Compared with their respective controls, all cybrid cell lines showed a similar and
moderate decrease in oxygen consumption, which was significant for the ND6 and triple H
Table 2. Cybrid cell lines used in this study.
Haplogroup Mutation Cybrid line Clone
J1c Wt K (J1c) K (J1c) 1
K (J1c) 2
m.11778G>A ND4 (J1c) ND4 (J1c) 1
ND4 (J1c) 2
Uk1 Wt K (Uk1) K (Uk1) 1
K (Uk1) 2
m.14484T>C ND6 (Uk1) ND6 (Uk1) 1
ND6 (Uk1) 2




m.11778G>A m.14484T>C m.11253T>C TRIPLE (H) TRIPLE (H) 1
TRIPLE (H) 2
* Clones 1 and 2 are from a different family pedigree than 3 and 4.
doi:10.1371/journal.pone.0146816.t002
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Fig 1. Cybrids carrying the triple mutation show similar biochemical parameters to those with single mutations. (A) Growth analysis of control and
mutant cell lines. Cells were grown in glucose or galactose to evaluate their mitochondrial function. Lines represen the mean of two different clones
measured in three independent experiments. Error bars represent standard deviation. (B) Lactate production was measured in culture medium following a
48-h culture period and normalized to total amount of protein. (C) Mitochondrial inner membrane potential was evaluated as the ratio of TMRE and MTG
fluorescence by flow cytometry. (D) Oxygen consumption of 4×106 cells was recorded for 30 minutes using a Clark-type O2 electrode. (E) Mitochondrial
steady-state ATP was measured in cells incubated with 5 mM 2-deoxy-D-glucose and 1 mM pyruvate for 2.5 h. ATP was normalized to the total amount of
protein. Bars in histograms are the mean from two different clones measured in three independent experiments. Data are represented as percentage relative
to their haplogroup control. Error bars indicate standard deviation. * p<0.05 determined by one way ANOVA followed by Tukey´s test for multiple
comparisons.
doi:10.1371/journal.pone.0146816.g001
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mutations (Fig 1D). These results are consistent with those previously described in the LHON
literature [13, 15, 41–43], confirming that a complex I dysfunction leads to a decrease in respi-
ratory capacity.
ATP production is a frequently measured parameter in mitochondrial pathology and partic-
ularly in LHON studies since its synthesis is the terminal step of OXPHOS. Most studies
describe a severe reduction in mitochondrial ATP production by the three common LHON
mutations and, consequently, it is proposed as one of the key factors in the pathophysiology of
the disease [44, 45]. As anticipated, mitochondrial steady-state ATP levels were significantly
decreased by approximately 50% in all cybrid cells tested and no differences were detected
between the different mutant cell lines (Fig 1E).
Complex I performance: enzymatic activity and superoxide production
Generation of complex I deficiencies by the three primary LHONmutations is commonly
accepted. However, the degree of deficiency is controversial because of the marked variability
described in the literature, in part due to differences in experimental approaches. Accordingly,
complex I deficiency ranges from a weak to an 80% reduction in specific activity when com-
pared with controls [41]. This variability also depends on the mutation and only m.3460G>A
(ND1) was invariably described to cause a substantial and significant decline of complex I
activity [46]. By contrast, a modest decrease of enzyme activity was observed in several studies
analyzing mutations in the ND6 subunit (m.14484T>C) [42] or in ND4 (m.11778G>A) [41,
47]. Remarkably, in the unique double LHON study with available biochemical data for com-
plex I, the proband presented consistently lower complex I activity than those harboring single
mutations [15].
The specific activity of the respiratory chain complexes was measured in cybrid cell lines
and normalized to citrate synthase activity. A significant decrease in complex I activity was
detected in all mutant cybrid lines (of approximately 50%), with no significant differences
between the mutations (Fig 2A). To evaluate whether the mutations were associated with an
isolated complex I defect, the activity of complex II, complex III and complex IV was also mea-
sured in the triple LHON cell line and haplogroup H control cells. No differences were detected
in the other OXPHOS complexes, confirming the isolated complex I defect (Fig 2B).
ROS production is generally associated with impairments of the respiratory chain. It has
been hypothesized that, in addition to an ATP synthesis defect, increased ROS production may
be responsible for the neurodegeneration effects underlying LHON [13]. Since impairment of
electron flow through complex I leads to a higher proportion of reduced FMN that reacts with
oxygen, increasing superoxide formation [48–50], we hypothesized that higher ROS levels
could be present in cybrid mutants. Accordingly, mitochondrial superoxide production was
evaluated with MitoSOXTM and significantly increased levels of superoxide were detected in
cybrid lines containing mtDNA from LHON patients as compared with their respective con-
trols (Fig 2C). However, the differences were not significantly different between the triple
LHONmutant and the single mutants. These results are in accordance with the proposed
model of ROS generation and with the biochemical characterization and complex I activity,
and demonstrate that the triple mutant does not generate more ROS since it has no additional
mitochondrial defect.
Complex I assembly
The importance of respiratory chain supercomplexes has been demonstrated by numerous
studies in recent years [51–53], but their precise function and clinical relevance is still unclear.
Nevertheless, it seems reasonable that supercomplexes would confer an advantage by physically
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facilitating electron transfer through the intimate association of different components of the
ETC, thereby enhancing the efficiency of the process and decreasing the collateral ROS produc-
tion [53]. A delayed kinetic of OXPHOS complex assembly has been postulated as a key factor
in LHON pathogenesis, and the association of specific haplogroups with the primary LHON
mutation is considered one of the possible modulating factors for the disease [27, 54]. In these
Fig 2. Complex I performance: mutants show the same extent of decreased complex I enzymatic
activity and increased ROS production to controls. (A) Enzymatic activity of complex I was measured in
all cell lines. (B) Complex II, complex III and complex IV activity in cybrids lines harboring the triple mutation
and their controls from haplogroup H. In B and C, data for each cell line was normalized to the activity of
citrate synthase and represented as percentage of their control haplogroup. (C) Superoxide levels were
measured with MitoSOXTM and flow cytometry. Data for all the experiments represent the mean of two
independent clones from three experiments. Error bars are the standard deviation. * p<0.05 determined by
one way ANOVA followed by Tukey´s test for multiple comparisons.
doi:10.1371/journal.pone.0146816.g002
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studies, the deleterious effect of the mutations for the performance of the ETC could be exacer-
bated under stress conditions due to a diminished proportion of assembled supercomplexes.
We analyzed the steady-state levels of complex I and the kinetics of its assembly. The former
was carried out in triple LHON cybrid cells and their haplogroup controls by BN-PAGE. Com-
plex II was used as an internal reference to account for variations in the mitochondrial mass.
No significant differences were observed in the steady-state levels of fully assembled complex I
in the triple mutant as compared with the wild-type haplogroup control cells (Fig 3A), as previ-
ously described for other LHON cybrids [54]. To analyze the kinetics of complex I assembly,
we first depleted the OXPHOS protein complexes by chloramphenicol treatment. Analysis of
subassembly patterns by two-dimensional BNSDS-PAGE of the triple LHON cybrids and con-
trols demonstrated a similar assembly recovery (Fig 3B), strongly suggesting that triple LHON
Fig 3. Assembly of complex I is not altered in the triple mutant. (A) Left panel: Steady-state levels of fully
assembled complex I were evaluated in the triple mutant cybrid clones and in controls by BN-PAGE. Fully
assembled complex I, and complex II, was determined by western blotting using antibodies recognizing
NDUFA9 and CII 70 kDa, respectively. Right panel: quantification of 4 control clones and 2 triple clones from
two independent gels and normalized to complex II, represented as percentage of the controls. (B)
BN-SDS-PAGE of individual clones after 48 h of recovery from chloramphenicol treatment (see Materials and
methods). Experiments were performed at least by duplicate. SC indicates supercomplexes containing
complex I.
doi:10.1371/journal.pone.0146816.g003
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mutants do not have a complex I assembly defect, in contrast to previous results with some sin-
gle mutation [54].
[Ca2+]M measurements
Mitochondrial Ca2+ uptake is strictly dependent on mitochondrial membrane potential and is
a good parameter of mitochondrial function [55]. We measured mitochondrial Ca2+ uptake in
triple LHON cybrids with or without permeabilzation of the cells. Mitochondrial Ca2+ uptake
was triggered by stimulation of intact cells with histamine to release Ca2+ from the endoplasmic
reticulum. Using permeabilized cells, mitochondrial Ca2+ uptake was directly induced by per-
fusion of a controlled [Ca2+] buffer. Neither agonist-induced (Fig 4A and 4B) nor perfusion-
induced (Fig 4C and 4D) Ca2+ mitochondrial uptake was affected in the triple mutated cybrids.
Since it is well documented that mitochondrial dysfunction leads to mitochondrial calcium
alterations [55, 56], our results suggest that the LHONmutations described here are not suffi-
ciently severe to alter mitochondrial Ca2+ homeostasis.
Discussion
We evaluated mitochondrial dysfunction caused by the first described case described of a
mtDNA molecule harboring three LHON associated mutations in comparison with two of the
most common single mutations causing LHON and their corresponding haplogroup controls.
Fig 4. The triple LHONmutation does not affect mitochondrial [Ca2+] homeostasis.Mitochondrial Ca2+
uptake was measured under two different conditions in control cybrids and in cybrids harboring the triple
mutation. (A) Intact cells were stimulated with 100 μM histamine, an agonist that induces Ca2+ release form
the endoplasmic reticulum. The traces depict the mean of four experiments. (B) Integration of means ± SD of
the peak heights (peak-basal) obtained in four measurements performed in each clone. The differences were
not significant (one-way ANOVA test). (C) A 4.5 μMCa2+ buffer was perfused in permeabilized cells as
indicated. The traces depict the mean of three similar experiments. (D) Bars show the mean ± SD of the rates
of [Ca2+]M increase obtained in three independent experiments. No significant differences were obtained.
doi:10.1371/journal.pone.0146816.g004
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Studies of the most frequent LHONmutations in the literature indicate that these mutations
are usually responsible for a subtle defect in mitochondrial function. Therefore, if the coexis-
tence of three non-severe mutations has additive effect on mitochondrial function it should be
easily detected. Moreover, because we used different clones with identical nuclei for each muta-
tion under the same experimental conditions, our results reconcile some conflicting data in the
literature regarding the impact of LHONmutations, probably as a consequence of differences
in experimental methods and materials.
All functional and biochemical parameters analyzed in this study correlated well with each
other and with the expected results, and revealed a defective OXPHOS system with a concomi-
tant increase in glycolysis in all the cybrid cell lines harboring LHONmutations. The only
exceptions to this were the calcium dynamics and the complex I assembly kinetics.
The involvement of mitochondria in calcium homeostasis is well documented [55, 57]. Fur-
thermore, alterations in calcium homeostasis have been described in several severe mitochon-
drial pathologies [56, 58]. However, the relationship between LHON and calcium homeostasis
in a cybrid model has been described in only one study [59]. Accordingly, in teratoma-derived
cybrids, the m.11778G>A (ND4) mutation alters the calcium buffering ability of mitochon-
dria. However, in our osteosarcoma-derived cybrid model, we failed to find any disarrange-
ment in calcium homeostasis for the potentially more severe triple LHONmutation, possibly
suggesting that the MIMP decrease in LHON 143B-derived cybrids is not sufficient to alter cal-
cium import into mitochondria.
The assembly of the respiratory chain complexes is essential to maintain a proper OXPHOS
function; indeed, defects in this highly regulated process are associated with different patholo-
gies [60]. Alterations of complex I assembly have been described in LHON, suggesting a possi-
ble mechanism for the pathogenesis of the disease pathogenesis [54]. However, no defect in
complex I assembly was detected in the triple mutant in the present study. We conclude from
this that the mild OXPHOS impairment caused by LHONmutations was not the result of an
assembly defect in complex I.
It is clear that the three simultaneous mutations do not exert an additive effect on complex I
or mitochondrial dysfunction since none of the studied parameters showed a more severe
defect in the triple LHON cybrids compared with cybrids carrying either m.11778G>A or
m.14484T>C single mutations. A study of the isolated m.11253T> C mutation would be inter-
esting to rule out the rare possibility of a compensating effect, unfortunately, we did not have
access to patients harboring this mutation.
To our knowledge, this is the first exhaustive study on the potential synergistic effect of con-
comitant LHON-associated mutations. We carried out a rigorous and controlled analysis of
mtDNA mutations independent of potentially confounding factors, including nuclear DNA,
mtDNA haplogroup and copy number and environment or experimental conditions. Further-
more, we evaluated a large number of molecular parameters in batch experiments and all of
them point to the absence of a synergistic effect among the three concomitant LHONmuta-
tions analyzed. These results are consistent with the clinical characteristics of the patient, who
presents a phenotype similar to many other patients harboring single LHONmutations,
including those studied in this work. The similar alteration in mitochondrial activity we
observe in our cell lines when compared with the clinical and molecular disorders shown in
patients and other cell systems strongly suggests a relevant role for ancillary factors in the
expression of this disease [11].
A possible, but speculative, explanation for why concomitant mutations in different sub-
units of a multiprotein complex produce a phenotype equivalent to that observed with single
mutations involves the structure/function relationship and interactions of subunits. Notwith-
standing the different proposed functions of ND4 and ND6, the m.11778G>A (ND4) and
Concomitant MtDNA LHONMutations Shows No Synergy
PLOS ONE | DOI:10.1371/journal.pone.0146816 January 19, 2016 14 / 19
m.14484T>C (ND6) mutations affect complex I function in an indistinguishable molecular
manner and produce the same phenotype in patients, LHON. The simplest interpretation
would be to consider that although different single mutations alter the interactions between
complex I subunits, the final functional outcome is the same. Concomitant mutations would
result in a disruption in proton and electron flow similar to that observed with the more delete-
rious single mutation, and would be a limiting factor. Since the single LHONmutations ana-
lyzed caused similar complex I defects, perhaps through a common pathogenic mechanism, an
additive effect might not be produced when they coexist.
Nevertheless, it is difficult to make a theoretical prediction about putative synergistic effects
of co-occurring mutations in the same complex, particularly if many structural and functional
aspects of that complex are still unknown, which is the case for respiratory chain complex I.
Moreover, the discrepancies in the literature on LHON patients, and different cellular models
used, cannot exclude the involvement of particular forms of nuclear subunits, which could
modulate, positively or negatively, the integration of all nuclear and mitochondrial subunits
and, consequently, the molecular and clinical phenotype. Undoubtedly, much more work is
still necessary to unravel the complex relationships among concomitant mutations in mtDNA.
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